专利检索 ap:("Dana-Farber Cancer Institute, Inc." OR "Voronoi Inc.") AND inv:"SON, Jungbeom" 第 1 页

1.

发明公开
PYRROLOPYRIMIDINE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 审中-公开

公开(公告)号：EP3968990A1

公开(公告)日：2022-03-23

申请号：EP20804945.2

申请日：2020-05-15

申请人： Dana-Farber Cancer Institute, Inc. , Voronoi Inc.

发明人： GRAY, Nathanael S. , HATCHER, John , CHOI, Jieun , LEE, Sun-Hwa , CHOI, Hwangeun , KO, Eunhwa , KIM, Yeonsil , KIM, Daekwon , KIM, Namdoo , SON, Jungbeom

IPC分类号： A61K31/437 , C07D487/04 , A61P25/28

2.

发明公开
ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES 审中-实审

公开(公告)号：EP4421077A1

公开(公告)日：2024-08-28

申请号：EP22884103.7

申请日：2022-10-21

申请人： Voronoi Inc.

发明人： JO, Seohyun , MA, Dahoon , PARK, Yeseul , SIM, Gyuseok , SON, Jungbeom , KIM, Namdoo , KIM, Sunghwan

IPC分类号： C07D487/04 , A61K31/5025 , A61K31/4439 , A61K31/422 , C07D413/14 , C07D513/04 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04

CPC分类号： A61K31/422 , A61K31/4439 , A61K31/5025 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04

摘要： The present invention relates to an aryl or heteroaryl derivative and a pharmaceutical composition for the treatment of kinase-related diseases comprising same as an active ingredient. An aryl or heteroaryl derivative provided according to an aspect of the present invention exhibits excellent inhibitory activity against kinases, especially receptor-interacting serine/threonine-protein kinase 1 (RIPK1), and thus can be used as a therapeutic agent for RIPK1-related diseases.

3.

发明公开
HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT 无效

公开(公告)号：EP4335847A1

公开(公告)日：2024-03-13

申请号：EP22799010.8

申请日：2022-04-08

申请人： Voronoi Inc.

发明人： LEE, Younho , HWANG, Seonah , DO, Woomi , SHIM, Inseob , LEE, Hwa , SON, Jungbeom , KIM, Namdoo , KIM, Sunghwan , JUNG, Hongryul , YOO, Jihye

IPC分类号： C07D413/04 , A61K31/506 , A61K31/5377 , A61K31/5386 , A61P35/00 , C07D413/14 , C07D471/04 , C07D487/04 , C07D417/14

摘要： The present invention relates to an isoxazolidin-2-yl-substituted heteroaryl derivative and a pharmaceutical composition for cancer prevention or treatment, comprising the compound as an active ingredient. The compound exhibits high inhibitory activity against the wild type or mutants of at least one of ErbB2 and ErbB4 and thus can be useful for treating cancers in which ErbB2 and ErbB4 are expressed

4.

发明公开
QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 审中-实审

公开(公告)号：EP4424675A1

公开(公告)日：2024-09-04

申请号：EP22887724.7

申请日：2022-10-28

申请人： Voronoi Inc.

发明人： JUNG, Myungho , JEON, Hyeonho , SON, Jungbeom , KIM, Namdoo , KIM, Sunghwan

IPC分类号： C07D239/74 , A61K31/517 , A61P35/00 , A61P3/04 , A61P25/00 , A61P9/10 , A61P9/12 , C07D401/12 , C07D487/10 , C07D403/12

CPC分类号： A61K31/517 , A61P3/04 , A61P9/10 , A61P9/12 , A61P25/00 , A61P35/00 , C07D239/74 , C07D401/12 , C07D403/12 , C07D487/10

摘要： The present disclosure relates to quinazoline derivative compounds and medicinal uses thereof. Specifically, the present disclosure provides compounds capable of treating or preventing c-KIT or PDGFR-related diseases by inhibiting c-KIT or PDGFR.